NCT06204159View on ClinicalTrials.gov

Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery

NAActive, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
Hepatocellular CarcinomaNeuroendocrine Tumors
Interventions
DEVICE

TACE Catheters

"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"

Trial Locations (2)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

University of Pennsylvania, Department of Radiology, Interventional Radiology Division, Philadelphia

All Listed Sponsors
collaborator

TriSalus Life Sciences, Inc.

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT06204159 - Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery | Biotech Hunter | Biotech Hunter